Immune Thrombocytopenia
We recommend
How do patients perceive the treatment of ITP with romiplostim?
Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
Central European Expert Consensus on the Treatment of ITP in Adult Patients
In a recently published consensus, experts from Central Europe evaluate the current treatment…
ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in…
Articles on this topic
Romiplostim Before Splenectomy in a Patient with ITP - Case Report
In the following case report from authors at a university hospital in Barcelona, the…
Options for Tapering TPO-RA in ITP Patients: Practical Experience and Expert Consensus
A recently published British study aims to provide recommendations on tapering TPO-RA in…
Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
This case report from the United States features an ideal therapeutic response to romiplostim…
ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 – Case Study
There can be numerous causes of newly acquired immune thrombocytopenia (ITP), often being…
Development of Immune Thrombocytopenia as a Result of Past COVID-19 Illness
Immune thrombocytopenia (ITP) developing secondary to COVID-19 is a completely new experience…
Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP
Recommendations for the care of acute, especially major bleeding in individuals with severe…
Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP
What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of…
Current and Future Possibilities for Influencing Immune Thrombocytopenia
The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a…
Romiplostim in a Pregnant Woman − Case Report
The following clinical case demonstrates good control of resistant immune thrombocytopenia in…
The Immune System in the Pathophysiology of ITP
From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- COVID-19 and Immune Thrombocytopenic Purpura − Spanish Experience Suggests Surprising Connections
- Idiopathic Thrombocytopenic Purpura with SARS-CoV-2 Infection
- Thrombocytopenia Following mRNA Vaccination Against SARS-CoV-2
- Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective
- Summary of Recommendations for the Treatment of Immune Thrombocytopenia in Pregnancy
- Current ASH Guidelines on ITP Management 2019 – Recommendations for Newly Diagnosed ITP in Children
Journal on this topic
Related topic